Global Cancer Technology is a non-revenue biopharma company developing a novel treatment for a deadly brain disease call glioblastoma, or GBM.Our drug is a small molecule PI3K inhibitor that can cross the blood brain barrier and is showing great promise in preclinical animal studies.
Worldwide, the number of new GBM cases per year is approximately 250,000 and, in the US, alone there are approximately 14,000 new cases per year. The life expectancy of a GBM patient is 15 months from the time of diagnosis. For children that have a special form of GBM, the life expectancy is 9 months from the time of diagnosis.
Our same PI3K inhibitor drug has shown highly encouraging preclinical trial results when used for triple negative breast cancer.
John Clark is a seasoned and serial entrepreneur with deep expertise in medical technologies. In this video, he offers insights into some of the technology available to GCT and how their innovative approach drug delivery using remote-control for exceptional precision and timing. Our non-invasive technology has the potential to change the game for cancer patients.
And it takes time …. but you can help. We’re NOT seeking donations – you can buy stock in our company now to fund our research.
Global Cancer Technology (GCT) has acquired numerous patented technologies: Not only are developing a unique PI3K inhibitor drug for glioblastoma, but we are exploring technologies to attach the drug to nanoparticles and activate the drug within the tumor! Our initial focus is brain cancer (glioblastoma), but the approach may have potential in the treatment of other forms of cancer and other diseases. GCT is working with the world-renowned scientists of the Barrow Neurological Institute, Baylor Scott & White Hospital and Imagion Biosystems. We have recently initiated preclinical studies using our drug for triple negative breast cancer at the University of Colorado-Anschutz Medical Campus
Everyone knows someone affected by cancer.
Each year, in the USA alone, according to Cancer.org, nearly two million people are diagnosed with some form of cancer. Over the last two decades, tremendous progress has been made with new treatments but there is still room for improvement.
Each year, about one-third of those diagnosed with cancer (605,500) will die from this deadly disease.
Glioblastoma, which is a rare form of brain cancer, is diagnosed in about 5 of every 100,000 people worldwide and incidence is increasing according to studies published by the NCBI.
Crossing the blood-brain barrier has been the limiting factor in developing new treatments. We believe we have a solution.
We have taken an innovative approach to developing new treatments. By in-licensing technologies, and then combining them in a unique way, we believe that we can develop an effective treatment for glioblastoma faster, and at a lower cost, than if we started from “scratch” independently. Collaboration is a critical aspect of our approach.
We are focused on three key technologies:
Once we have established safety and efficacy standards per the requirements of the FDA, we will be seeking partners to advance our treatment through progressive clinical trials and then to commercialize it
Research takes time. And money. Bringing a drug to market now costs and average of $1.3 Billion and at least a decade. It’s extremely challenging: with less funding, it takes even longer. Yet the potential to change lives makes it an attractive pursuit despite the complexity and risks.
CEO & founder
Chief Scientific Consultant